Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Older periods Mar '24 Jun '24 Sep '24 Dec '24
Piotroski F-Score

+8 more TTM periods

1 4 3 3
ROE
478.19% 203.46% 175.12% 164.62%
ROA
(79.92%) (119.30%) (145.76%) (605.73%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
393.45% 215.72% 184.72% 188.28%
Average Days of Receivables
169.05 132.33 65.37 14.11
Free Cash Flow per Share
(3.93) (3.23) (3.34) (4.12)
Free Cash Flow
(13.05) (12.54) (15.74) (17.34)
Other line items

Show all line items

Columns are period end dates